We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Integra LifeSciences Holdings Corporation (IART) Hits Fresh High: Is There Still Room to Run?
Read MoreHide Full Article
Have you been paying attention to shares of Integra LifeSciences (IART - Free Report) ? Shares have been on the move with the stock up 23.7% over the past month. The stock hit a new 52-week high of $18.19 in the previous session. Integra has gained 40.6% since the start of the year compared to the -4.2% move for the Zacks Medical sector and the -16.9% return for the Zacks Medical - Instruments industry.
What's Driving the Outperformance?
The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on May 5, 2026, Integra reported EPS of $0.54 versus consensus estimate of $0.41 while it beat the consensus revenue estimate by 2.74%.
For the current fiscal year, Integra is expected to post earnings of $2.42 per share on $1.67 in revenues. This represents a 8.52% change in EPS on a 2.24% change in revenues. For the next fiscal year, the company is expected to earn $2.57 per share on $1.73 in revenues. This represents a year-over-year change of 6.3% and 3.27%, respectively.
Valuation Metrics
While Integra has moved to its 52-week high over the past few weeks, investors need to be asking, what is next for the company? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
Integra has a Value Score of B. The stock's Growth and Momentum Scores are B and F, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 7.2X current fiscal year EPS estimates, which is not in-line with the peer industry average of 23.1X. On a trailing cash flow basis, the stock currently trades at 4.1X versus its peer group's average of 13.3X. Additionally, the stock has a PEG ratio of 1.22. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks Rank
We also need to look at the Zacks Rank for the stock, as this is even more important than the company's VGM Score. Fortunately, Integra currently has a Zacks Rank of #2 (Buy) thanks to a solid earnings estimate revision trend.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Integra passes the test. Thus, it seems as though Integra shares could have potential in the weeks and months to come.
View the Zacks #1 Rank List
Image: Bigstock
Integra LifeSciences Holdings Corporation (IART) Hits Fresh High: Is There Still Room to Run?
Have you been paying attention to shares of Integra LifeSciences (IART - Free Report) ? Shares have been on the move with the stock up 23.7% over the past month. The stock hit a new 52-week high of $18.19 in the previous session. Integra has gained 40.6% since the start of the year compared to the -4.2% move for the Zacks Medical sector and the -16.9% return for the Zacks Medical - Instruments industry.
What's Driving the Outperformance?
The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on May 5, 2026, Integra reported EPS of $0.54 versus consensus estimate of $0.41 while it beat the consensus revenue estimate by 2.74%.
For the current fiscal year, Integra is expected to post earnings of $2.42 per share on $1.67 in revenues. This represents a 8.52% change in EPS on a 2.24% change in revenues. For the next fiscal year, the company is expected to earn $2.57 per share on $1.73 in revenues. This represents a year-over-year change of 6.3% and 3.27%, respectively.
Valuation Metrics
While Integra has moved to its 52-week high over the past few weeks, investors need to be asking, what is next for the company? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
Integra has a Value Score of B. The stock's Growth and Momentum Scores are B and F, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 7.2X current fiscal year EPS estimates, which is not in-line with the peer industry average of 23.1X. On a trailing cash flow basis, the stock currently trades at 4.1X versus its peer group's average of 13.3X. Additionally, the stock has a PEG ratio of 1.22. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks Rank
We also need to look at the Zacks Rank for the stock, as this is even more important than the company's VGM Score. Fortunately, Integra currently has a Zacks Rank of #2 (Buy) thanks to a solid earnings estimate revision trend.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Integra passes the test. Thus, it seems as though Integra shares could have potential in the weeks and months to come.